AlphaMadera's AlphaVal page computes Colgate-Palmolive Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag CL as undervalued, fairly valued, or overvalued.

What is Colgate-Palmolive Company's fair value?

Fair value for CL is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value CL?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from CL's most recent reported fundamentals.

CL - Colgate-Palmolive Company

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $94.90 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong

Trading 47.4% above fair value

Current Price $90.61

Bear Case $50.62 44.1% downside ($50.62 - $90.61) / $90.61 = -44.1% $2.77 × 14x P/E

Fair Value $61.45 32.2% downside ($61.45 - $90.61) / $90.61 = -32.2% $2.77 × 17x P/E

Bull Case $72.30 20.2% downside ($72.30 - $90.61) / $90.61 = -20.2% $2.77 × 20x P/E

Adjust Assumptions

P/E Multiple

17.0x

Adjusted EPS

2.77$

Key Value Driver

Normalized P/E multiple (17x base case)

Implied Market Multiple 32.7x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $94.90 from 45 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $61.45 per share.

Warnings

ℹ Wall Street's average price target is $94.90 (from 45 analysts). Our estimate is 50% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples